natgillin/translations-raw huggingface dataset:
Capsule according to any of claims 1 to 5, characterized in that the passageways (9e, 9e') disposed in the zone (2) suitable to face the flow upstream, are provided in a number, distribution, including radial distribution, dimension and spatial orientation such that the pressurized flow of fluid is projected to at least one distance reach, preferentially to at least two distance reaches, along the radial direction of the capsule, and distributed in uniform or substantially asymmetric way relative to the perimeter of the section of flow passageway. 
Kapsula u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da su prolazi (9e, 9e') koji se nalaze u zoni (2) prikladnoj za okretanje prema protoku uzvodno, postavljeni u broju, rasporedu, uključujući radijalni raspored, veličini i prostornoj orijentaciji tako da protok tekućine pod tlakom doseže do najmanje jedne udaljenosti, a poželjno je do najmanje dvije udaljenosti duž radijalnog smjera kapsule i raspoređeni ujednačeno ili uglavnom na asimetrični način u odnosu na obod presjeka prolaza protoka.
Capsule according to any of claims 1 to 6, characterized in that the passageways (9e, 9s; 9e', 9s') of the controlled opening element (5e, 5s) and/or respective element fixture (6e, 6s), present a dimension and/or format that varies in each case at least along the respective perimeter. 
Kapsula u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time, da prolazi (9e, 9s; 9e', 9s') kontroliranog elementa za otvaranje (5e, 5s) i / ili odgovarajući element za pričvršćivanje (6e, 6s),ima veličinu i / ili oblik koji se razlikuje u svakom slučaju, barem duž odgovarajućeg opsega.
fixating said capsule (1, 1') in the extraction chamber (10), by means of mechanical clamping, preferentially between an infusion head (11) and an infusion discharge (12), 
fiksiranje navedene kapsule (1, 1') u komoru za ekstrakciju (10) mehaničkim stezanjem, poželjno između glave za infuziju (11) i pražnjenja infuzije (12),
Process according to claims 11 or 12, characterized in that after beginning of the flow injection of pressurized fluid, the latter is immediately introduced inside the capsule (1, 1') through the, at least one, passageway (9e; 9e') of the controlled opening element (5e) and/or respective element fixture (6e). 
Postupak u skladu s patentnim zahtjevom 11 ili 12, naznačen time, da se nakon početnog ubrizgavanja protoka tekućine pod pritiskom, potonji odmah uvodi unutar kapsule (1, 1') kroz najmanje jedan prolazni otvor (9e; 9e') kontroliranog elementa za otvaranja (5e) i / ili odgovarajućeg elementa za pričvršćivanje (6e).
Device for using a capsule (1, 1') according to any one of claims 1 to 10, characterized in that it comprises at least one extraction chamber (10) to carry out the process according to any of claims 11 to 14. 
Uređaj za korištenje kapsule (1, 1') u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time, da sadrži najmanje jednu komoru za ekstrakciju (10) za provođenje postupka prema bilo kojem od patentnih zahtjeva 11 do 14.
Structure according to any one of claims 1 to 5, characterized in that the longitudinal members (36) are made by mutually connectable profiled sections, having an overturned U cross-section. 
Konstrukcija prema bilo kojem od zahtjeva 1 do 5, naznačena time, da su longitudinalni nosači (36) izrađeni pomoću zajedno spojivih profilnih odsječaka koji imaju poprečni presjek kao obrnuto slovo U.
n represents from 0 to 4; and m represents 1. 
n predstavlja od 0 do 4; i m predstavlja 1.
A compound of formula I according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof for use in treatment of a disease mediated by the TCR-Nck interaction in T lymphocytes, where the disease is selected from rejection of transplants, rheumatoid arthritis, psoriatic arthritis, psoriasis, type I diabetes, complications of diabetes, multiple sclerosis, systemic lupus erythematosus, atopic dermatitis, mast cell-mediated allergic reactions, leukemias, lymphomas and thromboembolic and allergic complications associated with leukemias and lymphomas. 
Tvar formule I u skladu s bilo kojim od patentnih zahtjeva 1 do 6 ili njena farmaceutski prihvatljiva sol za uporabu u liječenju bolesti posredovane međudjelovanjem TRC-Nck u T-limfocitima, pri čemu je bolest odabrana između odbacivanja transplantata, reumatoidnog artritisa, psorijatičnog artritisa, psorijaze, dijabetesa tipa I, komplikacija dijabetesa, multiple skleroze, sustavnog eritemskog lupusa, atopijskog dermatitisa, alergijskih reakcija posredovanih mast stanicama, leukemija, limfoma i tromboembolijskih i alergijskih komplikacija povezanih s leukemijama i limfomima.
reacting a compound of formula II with a compound of formula III Cy1-H III where R1, R2, R3, Cy1, n and m have the meaning described in claim 1; and/or 
reagiranje tvari formule II s tvari formule III [image] gdje R1, R2, R3, Cy1, n i m imaju značenje opisano u patentnom zahtjevu 1; i/ili
Y is wherein ring A is a benzene ring which is optionally further substituted; 
Y je: [image] gdje prsten A je benzen-prsten koji je opcijski dodatno supstituiran;
Z is a group represented by -NR3CO-, -NR3CO-W1-, 
Z je skupina predstavljena sa sljedećim formulama:
phenyl optionally having 1 to 3 substituents selected from 
fenil koji opcijski ima 1 do 3 supstituenta odabrana od sljedećih:
a C1-6 alkyl optionally having 1 to 3 substituents selected from 
C1-6 alkil koji opcijski ima 1 do 3 supstituenta odabrana od sljedećih:
cyano, a C1-6 alkoxy optionally having 1 to 3 substituents selected from 
C1-6 alkoksi koji opcijski ima 1 do 3 supstituenta odabrana od sljedećih:
a 5- or 6-membered monocyclic aromatic heterocyclic group optionally having 1 to 3 substituents selected from 
5-člana ili 6-člana monociklička aromatska heterociklička skupina koja opcijski ima 1 do 3 supstituenta odabrana od sljedećih:
A compound of the general formula (I), wherein 
Spoj s općom formulom (I), [image] naznačen time da
is -C(O)-R4, -S(O)2-R4,, substituted or unsubstituted cycloalkyl, aryl or heteroaryl; wherein substituents, may be one or more and are independently selected from hydrogen, hydroxy, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy; 
je -C(O)-R4, -S(O)2-R4, [image] supstituiran ili nesupstituiran cikloalkil, aril ili heteroaril; pri čemu supstituenata može biti jedan ili više, te su neovisno odabrani od vodika, hidroksi, halogena, alkila, alkoksi, haloalkila ili haloalkoksi;
is substituted or unsubstituted alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl or heterocyclylalkyl; wherein substituents, may be one or more and are independently selected from hydrogen, hydroxy, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy; 
je supstituiran ili nesupstituiran alkil, cikloalkil, cikloalkilalkil, aril, heteroaril, heterociklil ili heterociklilalkil; pri čemu supstituenata može biti jedan ili više, te su neovisno odabrani od vodika, hidroksi, halogena, alkila, alkoksi, haloalkila ili haloalkoksi;
at each occurrence, R3 is independently selected from hydrogen, halo, alkyl or alkoxy; 
kod svake pojave, R3 je neovisno odabran od vodika, halo, alkila ili alkoksi;
is hydrogen, substituted or unsubstituted alkyl or cycloalkyl; wherein substituents, may be one or more and are independently selected from hydrogen, hydroxy, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy; 
je vodik, supstituiran ili nesupstituiran alkil ili cikloalkil; pri čemu supstituenata može biti jedan ili više, te su neovisno odabrani od vodika, hidroksi, halogena, alkila, alkoksi, haloalkila ili haloalkoksi;
The compound as claimed in claim 1, wherein R4 is alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl or heterocyclylalkyl. 
Spoj prema zahtjevu 1, naznačen time da R4 je alkil, cikloalkil, cikloalkilalkil, aril, heteroaril, heterociklil ili heterociklilalkil.
The compound as claimed in claim 1, which is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koju čine:
The pharmaceutical composition as claimed in claim 7, for use in the treatment of clinical conditions such as cognitive disorders, sleep disorders, obesity and pain. 
Farmaceutski pripravak kako je zatraženo u zahtjevu 7, naznačen time da je za upotrebu u liječenju kliničkih stanja, kao što su kognitivni poremećaji, poremećaji spavanja, pretilost i bol.
deprotecting the compound of formula (3) to form compound of formula (4), 
deprotekciju spoja s formulom (3) da se dobije spoj s formulom (4), [image]
coupling the compound of formula (4) with compound of formula (5) EPMATHMARKEREP to form a compound of formula (I), wherein all substitutions are as defined in claim 1, 
vezanje spoja s formulom (4) sa spojem s formulom (5) [image] da se dobije spoj s formulom (I), pri čemu su sve supstitucije definirane kao u zahtjevu 1,
bromination of compound of formula (7) to form compound of formula (8), 
bromiranje spoja s formulom (7) da se dobije spoj s formulom (8), [image]
cyclization of compound of formula (8) to form compound of formula (9), 
ciklizaciju spoja s formulom (8) da se dobije spoj s formulom (9), [image]
diazotization of compound of formula (9) to form compound of formula (10), 
diazotiranje spoja s formulom (9) da se dobije spoj s formulom (10), [image]
coupling the compound of formula (10) with compound of formula (2) to form compound of formula (I), wherein all substitutions are as defined in claim 1, 
vezanje spoja s formulom (10) sa spojem s formulom (2) [image] da se dobije spoj s formulom (I), pri čemu su sve supstitucije definirane kao u zahtjevu 1,
coupling the compound of formula (12) with compound of formula (2) to form a compound of formula (I), wherein all substitutions are as defined in claim 1, 
vezanje spoja s formulom (12) sa spojem s formulom (2) [image] da se dobije spoj s formulom (I), pri čemu su sve supstitucije definirane kao u zahtjevu 1,
A compound according to any one of claims 1 to 6, for use in the treatment of clinical conditions such as cognitive disorders, sleep disorders, obesity and pain. 
Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time da je za upotrebu u liječenju kliničkih stanja, kao što su kognitivni poremećaji, poremećaji spavanja, pretilost i bol.
A method for preparation of compound of formula (XXI), the method comprises a step (N); 
Postupak za pripremu spoja formule (XXI), [image] naznačen time da postupak obuhvaća korak (N);
Method according to claim 1, wherein the catalyst (N-cat) is selected from the group consisting of acetic acid, formic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, HCl, HBr, H2SO4, H3PO4, BCl3, BF3OEt2, MgCl2, MgBr2, AlCl3, ZnCl2, Cu(BF4)2, aluminosilicates, acidic ion exchange resins, carbon treated with HCl, H2SO4 or HNO3, and mixtures thereof. 
Postupak prema zahtjevu 1, naznačen time da je katalizator (N-kat.) odabran iz skupine koja se sastoji od octene kiseline, mravlje kiseline, trifluoroctene kiseline, metansulfonske kiseline, p-toluolsulfonske kiseline, HCl, HBr, H2SO4, H3PO4, BCl3, BF3OEt2, MgCl2, MgBr2, AlCl3, ZnCl2, Cu(BF4)2, aluminosilikata, kiselih smola ionskih izmjenjivača sa HCl, H2SO4 ili HNO3 tretiranim ugljikom i njihovih mješavina.
solvent (N-solv) is selected from the group consisting of water, tert-butanol, isopropanol, acetonitrile, propionitrile, THF, methyl-THF, NMP, dioxane, 1,2-dimethoxyethane, dichloromethane, 1,2-dichloroethane, chloroform, toluene, benzene, chlorobenzene, hexane, cyclohexane, ethyl acetate, acetic acid, formic acid, trifluoroacetic acid and mixtures thereof. 
otapalo (N-otap.) je izabrano iz skupine koja se sastoji od vode, terc.-butanola, izopropanola, acetonitrila, propionitrila, THF, metil-THF, NMP, dioksana, 1,2-dimetoksietana, diklormetana, 1,2-dikloretana, kloroforma, toluola, benzola, klorbenzola, heksana, cikloheksana, etilnog estera octene kiseline, octene kiseline, mravlje kiseline, trifluoroctene kiseline i njihovih mješavina.
reaction (O1-reac) is a reaction of compound of formula (XXIII) with water and with a compound (O1-comp); 
Kod reakcije (O1-reak.) se radi o reakciji (O1-reak.) spoja formule (XXII) sa vodom i jednim spojem (O1-spoj);
compound (O1-comp) is selected from the group consisting of bromine, N-bromosuccinimide, chlorine, N-chlorosuccinimide, iodine, N-iodosuccinimide, IBr, BrCl, and mixtures thereof; 
Spoj (O1-spoj) je odabran iz skupine broma, N-bromsukcinimida, klora, N-klorsukcinimida, joda, N-jodsukcinimida, IBr, BrCl i njihovih mješavina;
Method according to claim 4, wherein reagent (O-reag) is selected from the group consisting of peracetic acid, tert-butylhydroperoxide, oxygen, air, sodium hypochlorite, aqueous H2O2, H2O2 dissolved in acetic acid, H2O2 dissolved in trifluoroacetic acid, and mixtures thereof. 
Postupak prema zahtjevu 4, naznačen time da reagens (0-reag.) je iz skupine, koja se sastoji od peroctene kiseline, terc.-butilhidroperoksida, kisika, zraka, natrij hipoklorita, vodenastog H2O2, u octenoj kiselini otopljenog H2O2, u trifluoroctenoj kiselini otopljenom H2O2 i njihovih mješavina.
reagent (Q1-reag) is selected from the group consisting of lithium, magnesium, aluminum, zinc, calcium, isopropylmagnesium chloride, isopropylmagnesium bromide, butyllithium, sec-butyllithium and mixtures thereof; 
Reagens (Q1-reag.) je odabran iz skupine koja se sastoji iz litija, magnezija, aluminija, cinka, kalcija, izopropilmagnezijklorida, izopropilmagnezijbromida, butillitija, sec.-butillitija i njihovih mješavina;
reaction (Q2-reac) is a reaction of the reaction product of reaction (Q1-reac) with acetone; 
Kod reakcije (Q2-reak.) se radi o reakciji reakcijskog produkta rekacije (Q1-reak.) sa acetonom;
reagent (Q3-reag) is selected from the group consisting of water, methanol, ethanol, oxalic acid, citric acid, NH4Cl, HCl, HBr, HNO3, H2SO4, H3PO4, acetic acid, propionic acid, formic acid and mixtures thereof. 
Reagens (Q3-reag.) je odabran iz skupine koja se sastoji iz vode, metanola, etanola, oksalne kiseline, limunske kiseline, NH4Cl, HCl, HBr, HNO3, H2SO4, H3PO4, octene kiseline, propionske kiseline, mravlje kiseline i njihovih mješavina.
Use of compound of formula (XXI) for the preparation of medetomidine, with the compound of formula (XXI) as defined in claim 1. 
Primjena spoja formule (XXI) za spravljanje medetomidina, naznačen time da je spoj formule (XXI) definiran kao u zahtjevu 1.
The compound of claim 1 or 2, or the pharmaceutical composition of any of claims 3 to 6 for use in a method of treating, managing, or preventing a disease or disorder, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, hemoglobinopathy or a related disorder, or a TNFa related disorder. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5 za uporabu u postupku liječenja, održavanja stanja ili prevencije bolesti ili poremećaja, naznačen time, da je bolest ili poremećaj karcinom, poremećaj povezan s angiogenezom, boli, degeneracija žute pjege (makularna degeneracija) ili srodni sindrom, bolest kože, plućni poremećaj, poremećaj povezan s azbestozom, parazitska bolest, poremećaj imunodificijencije, poremećaj središnjeg živčanog sustava (CNS), ozljeda središnjeg živčanog sustava, ateroskleroza ili srodni poremećaj, poremećaj funkcije sna ili srodni poremećaj, hemoglobinopatija ili srodni poremećaj, ili poremećaj povezan s čimbenikom nekroze tumora alfa (TNFa).
A conjugate comprising an antibody of any one of claims 1-13 coupled to a therapeutic agent, wherein the therapeutic agent preferably is a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat obuhvaća protutijelo iz bilo kojeg od patentnih zahtjeva 1 do 5 vezano za terapijski agens, pri čemu je terapijski agens poželjno toksin, radioizotop, lijek ili citotoksični agens.
The antibody for use, conjugate for use or pharmaceutical composition for use of claim 34 wherein the disease or disorder is a tumor-related disease, wherein the tumor-related disease preferably is selected from the group consisting of breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, colorectal cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof. 
Protutijelo, konjugat ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 10 pri čemu je bolest ili poremećaj bolest povezana s tumorom, pri čemu je bolest povezana s tumorom poželjno odabrana iz grupe koja se sastoji od karcinoma dojke, karcinoma želuca, karcinoma jednjaka, karcinoma gušterače, karcinoma pluća, karcinoma jajnika, karcinoma debelog crijeva, kolorektalnog karcinoma, karcinoma jetre, karcinoma glave i vrata, karcinoma žučnog mjehura i njihovih metastaza.
The dsRNA defined in any one of Claims 1 to 7 for use in a therapeutic amount for treating a subject, said therapeutic amount preferably being for intravenous infusion; intradermal, subcutaneous, or intramuscular injection; intranasal or intratracheal inhalation; or intranasal, intratracheal, oropharyngeal, or sublingual application. 
DsRNK definirana prema bilo kojem od patentnih zahtjeva od 1 do 7 za upotrebu u terapeutskoj količini za liječenje subjekta, pri čemu je navedena terapeutska količina poželjno u obliku intravenske infuzije; intradermalne, subkutane ili intramuskularne inekcije; intranazalne ili intratrahealne inhalacije; ili intranazalne, intratrahealne, orofaringealne ili sublingvalne primjene.
The composition of Claim 8 for use in a therapeutic amount for treating a subject, said therapeutic amount preferably being for intravenous infusion; intradermal, subcutaneous, or intramuscular injection; intranasal or intratracheal inhalation; or intranasal, intratracheal, oropharyngeal, or sublingual application. 
Kompozicija prema patentnom zahtjevu 8 za upotrebu u terapeutskoj količini za liječenje subjekta, pri čemu je navedena terapeutska količina poželjno u obliku intravenozne infuzije; intradermalne, subkutane ili intramuskularne injekcije; intranazalna ili intratrahealna inhalacija; ili intranazalne, intratrahealne, orofaringealne ili sublingvalne primjene.
A process for the preparation of a compound of formula comprising the ring closure and dehydration of a compound of formula 
Postupak za pripravu spoja s formulom [image] naznačen time da se sastoji od zatvaranja prstena i dehidriranja spoja s formulom [image]
A process according to claim 1 wherein the compound of formula (35) is prepared by coupling a compound of formula with a compound having the formula 
Postupak prema zahtjevu 1 naznačen time da se spoj s formulom (35) priprema spajanjem spoja s formulom [image] sa spojem koji ima formulu [image]
A process according to claim 1 or claim 2 wherein the hydroxy function in the compound of formula (36) is converted to a leaving group. 
Postupak prema zahtjevu 1 ili zahtjevu 2 naznačen time da se hidroksi funkcionalnost u spoju s formulom (36) konvertira u izlaznu skupinu.
A process according to claim 3 wherein the leaving group is a halogen or an arysulfonyl group. 
Postupak prema zahtjevu 3 naznačen time da izlazna skupina je halogen ili arilsulfonil skupina.
A process as claimed in claim 9, wherein compound 43 is prepared according to the following scheme: 
Postupak prema zahtjevu 9, naznačen time da se spoj 43 priprema u skladu sa slijedećom shemom: [image] [image]
The modified release pharmaceutical composition of claim 1, which 
Farmaceutski oblik s prilagođenim otpuštanjem prema zahtjevu 1, koji,
when administered to a patient on a regular dosing schedule, provides a relatively flat plasma concentration profile of epalrestat at steady state, wherein there are no substantial peaks or troughs in the relatively flat plasma concentration profile and the minimum plasma concentration of epalrestat in the relatively flat plasma concentration profile is sufficient to provide a therapeutic effect to the patient; or 
kada se daje bolesniku u redovnom režimu doziranja, daje relativno ravan profil koncentracije epalrestata u plazmi u stanju ravnoteže, pri čemu nema bitnih pikova ili valova u relativno ravnom profilu koncentracije u plazmi i minimalna koncentracija epalrestata u plazmi u relativno ravnom profilu koncentracije u plazmi jest dovoljna da omogući terapijski učinak u bolesnika; ili
when administered to a patient on a regular dosing schedule, provides a relatively flat plasma concentration profile of epalrestat at steady state such that a mean Cmin/Cmax epalrestat ratio during dosing interval is about 0.55 to about 1.0, and the Cmin is sufficient to provide a therapeutic effect; or 
kada se daje bolesniku u redovnom režimu doziranja, daje relativno ravan profil koncentracije epalrestata u plazmi u stanju ravnoteže tako da je srednji omjer Cmin/Cmax epalrestata tijekom intervala doziranja oko 0,55 do oko 1,0 i Cmin jest dovoljan da omogući terapijski učinak; ili
provides to a patient a therapeutic effect for about 12 to about 24 hours and a relatively flat plasma concentration profile of epalrestat at steady state such that the minimum plasma concentration of epalrestat during the dosing interval is about 55% of the maximum plasma concentration during the dosing interval. 
jest oblik za doziranje jednom ili dva puta dnevno, daje bolesniku terapijski učinak kroz oko 12 do oko 24 sata i relativno ravan profil koncentracije epalrestata u plazmi u stanju ravnoteže tako da minimalna koncentracija epalrestata u plazmi tijekom intervala doziranja iznosi oko 55% maksimalne koncentracije u plazmi tijekom intervala doziranja.
The modified release pharmaceutical composition of claim 1, wherein epalrestat or a pharmaceutically acceptable derivative thereof is choline hydrogen diepalrestat. 
Farmaceutski oblik s prilagođenim otpuštanjem prema zahtjevu 1, gdje epalrestat ili njegov farmaceutski prikladan derivat jest kolin hidrogen diepalrestat ili betain hidrogen diepalrestat.
The modified release pharmaceutical composition of claim 1, for use in treating diabetes or a diabetic complication in a subject in need thereof. 
Farmaceutski oblik s prilagođenim otpuštanjem prema zahtjevu 1, za uporabu u postupku liječenja dijabetesa ili dijabetičke komplikacije kod subjekta kojem je to potrebno.
maintaining at least a minimum ORP level in such portion of water for at least a minimum period of time by dispensing an effective amount of chemical agent, wherein the minimum ORP level and the minimum period of time cannot be lower than the values calculated by: 
održavanje u najmanju ruku minimalne razine ORP u takvom dijelu vode za vrijeme u najmanju ruku minimalnog vremenski perioda doziranjem djelotvorne količine kemijskog sredstva, gdje minimalna razina ORP i minimalni vremenski period ne mogu biti manji od vrijednosti izračunatih:
for water temperatures from 5°C to 35°C, the minimum period of time is calculated by the following equation: EPMATHMARKEREP 
– za temperature vode od 5 °C do 35 °C, minimalni vremenski period izračunava sljedećom jednadžbom:
The method of claim 1, wherein the water body is a natural body of water. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je vodena površina prirodna vodena površina.
The method of claim 1, wherein the water body is selected from the group consisting of a lake, sea, estuary, dam, lagoon, spa, pool, pond and reservoir. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se vodenu površinu bira iz skupine koju čine jezero, more, riječno ušće, akumulacijsko jezero, laguna, toplice, bazen, bara i rezervoar.
The method of claim 1, wherein the water is fresh water, brackish water, salty water, or sea water. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je voda slatka voda, bočata voda, slana voda ili morska voda.
The method of claim 1, wherein the portion of water intended for recreational purposes is located on an edge or on the interior of a large water body. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dio vode namijenjen za rekreaciju nalazi na rubu ili u unutrašnjosti velike vodene površine.